Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03519984 · ClinicalTrials.gov registry record · Phase 1
EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia
A Phase 1 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03519984 is a Phase 1 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 3 participants.
The verdict
NCT03519984, a Phase 1 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with cytarabine or vincristine liposomal in treating participants with acute leukemia that has come back or has not responded to treatment. Drugs used in chemotherapy, such as recombinant ephb4-HSA fusion protein, cytarabine, and vincristine liposomal, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving the drugs in different combinations may kill more cancer cells.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Cytarabine
- BIOLOGICAL Recombinant EphB4-HSA Fusion Protein
- DRUG Vincristine Liposomal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-05-09 |
| Est. Completion | 2020-11-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03519984
The ClinicalTrials.gov registry entry for NCT03519984 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03519984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03519984 about?
NCT03519984 is a clinical study titled "EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia". This phase I trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with cytarabine or vincristine liposomal in treating participants with acute leukemia that has come back or has not responded to treatment. Drugs used in chemotherapy, such as recomb...
What is the current status of trial NCT03519984?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2018-05-09. Estimated completion is 2020-11-24.
What interventions are being tested in trial NCT03519984?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Cytarabine (DRUG), Recombinant EphB4-HSA Fusion Protein (BIOLOGICAL), Vincristine Liposomal (DRUG).
Who is sponsoring clinical trial NCT03519984?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.